



## GeoPharma Announces Second Quarter of Fiscal Year 2009 Earnings Conference Call

**LARGO, Fla., Nov. 5, 2008** (GLOBE NEWSWIRE) -- GeoPharma, Inc. (NasdaqCM:GORX - News) (the "Company") announced today that it will host a conference call to discuss the results of its second quarter which ended September 30, 2008. Financial results will be released after the market closes on Thursday, November 13, 2008 with the conference call to follow at 4:35 PM (ET). The conference call will be hosted by GeoPharma, Inc. CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Participants may dial in to register the day of the conference call 5 minutes before, or 4:30 PM. The dial in number for participants is 1-877-741-4239 and 719-325-4803 for international callers. The Conference Confirmation code is 6951540.

Listen via Internet: <http://gorx.client.shareholder.com/>

Schedule this webcast into MS-Outlook calendar (click open when prompted): <http://apps.shareholder.com/PNWOutlook/t.aspx?m=33777&k=7D66F3D2>

Replay of the call will be available at 7:35 PM ET until Midnight, Thursday November 27th. The Replay of the call may be heard by dialing 1-888-203-1112 or 1-719-457-0820 for international callers. The Replay Pass Code is 6951540. Participants may also choose to listen to the call via webcast through the link in the events and presentations section of the Investor Relations page of the GeoPharma website located at <http://www.geopharmainc.com>

For additional information Contact: Alexander Nachman, 727-471-0781 x 243, [IR@Geopharmainc.com](mailto:IR@Geopharmainc.com)

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide. GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively. Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities. For further information visit the "For Investors" section of the GeoPharma website at <http://www.geopharmainc.com>.

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

Contact:  
GeoPharma Inc.  
Alexander Nachman  
727-471-0781 x 243  
[IR@Geopharmainc.com](mailto:IR@Geopharmainc.com)